OXTR and migraine disorder: This study examined whether acute oxytocin receptor blockade provokes migraine attacks or alters cerebrovascular function.<h4>Methods</h4>In this randomized, double-blind, placebo-controlled, cross-over study, women with episodic migraine (WM), healthy women (HC), and men with episodic migraine (MM) aged 18-45 years received the oxytocin receptor antagonist atosiban (6.75 mg bolus followed by 54 mg over 3 h) or placebo on two separate visits.